Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

AD-LINK: Reversing Early Aβ-Driven Network Hyperexcitability

Objectif

Despite decades of research, there is currently no drug capable of preventing Alzheimer’s disease (AD), and ~99% of the drug candidates ultimately fail in clinical trials. This high failure rate is largely due to the lack of reliable preclinical models that enable continuous, longitudinal testing of therapeutic interventions from the earliest, pre-symptomatic stages of the disease.

AD‑LINK is a chronic neurotechnology platform designed to extract high‑resolution neurophysiological signatures of early AD across development and disease progression for longitudinal drug testing. Building on ERC‑funded discoveries showing that microglial dysfunction drives early network hyperexcitability, AD‑LINK addresses a fundamental limitation of current methods: no existing tool can provide stable, months‑long high‑density recordings while also enabling precise, localized perturbation of disease‑relevant pathways in freely moving animals. To meet the distinct needs of different disease stages, we will develop two complementary devices: (1) an ultra‑lightweight Neuropixels 2.0 drive for juvenile mice, enabling continuous tracking of the earliest circuit abnormalities during developmental onset; and (2) an integrated Liquid‑Ephys drive for adult mice, combining high‑density electrophysiology with controlled in situ delivery of soluble factors, allowing causal testing of how targeted interventions modulate — and potentially reverse — pathological circuit states. Through iterative engineering, in vivo validation, IP development, and structured engagement with industrial partners, this ERC PoC will deliver a de‑risked research platform that replaces insensitive behavioral endpoints with precise circuit‑level signatures. By enabling longitudinal, mechanistic analysis of early neuronal dysfunction and its modulation over time, AD‑LINK will strengthen the translational foundations of pre‑clinical AD research, thus aiming to increase success rate of AD drug candidates at clinical trials.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2026-POC

Voir tous les projets financés au titre de cet appel

Institution d’accueil

VIB VZW
Contribution nette de l'UE
€ 150 000,00
Adresse
SUZANNE TASSIERSTRAAT 1
9052 ZWIJNAARDE - GENT
Belgique
Région
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Type d’activité
Research Organisations
Liens
Coût total
Aucune donnée

Bénéficiaires (1)